Stock VRTX VERTEX PHARMACEUTICALS INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 07:15:11 16/07/2024 pm IST 		5-day change 1st Jan Change
493.2 USD +0.47% Intraday chart for Vertex Pharmaceuticals Incorporated +1.86% +20.63%
12:55pm Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $589 From $577, Maintains Buy Rating MT
15/07 Vertex Sues U.S. to Pay for Fertility Treatments DJ
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In

Latest news about Vertex Pharmaceuticals Incorporated

Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $589 From $577, Maintains Buy Rating MT
Vertex Sues U.S. to Pay for Fertility Treatments DJ
Vertex Files Lawsuit Against US Government to Pay for Fertility Treatment for Patients MT
Vertex sues US over fertility support program for Casgevy gene editing therapy RE
Vertex Pharmaceuticals Gets Health Canada Approval for Expanded Trikafta Use in Cystic Fibrosis Treatment MT
Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Marketing Authorization for Trikafa® for People with Cystic Fibrosis Aged 2 Years and Older with Certain Rare Mutations CI
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $455 From $402 MT
RBC Raises Price Target on Vertex Pharmaceuticals to $431 From $421, Keeps Sector Perform Rating MT
FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis MT
Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy DJ
Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, A Next-In-Class Triple Combination Treatment for Cystic Fibrosis CI
Verve Therapeutics, Inc. Announces Board and Committee Appointments CI
Redburn Atlantic Initiates Vertex Pharmaceuticals at Buy With $545 Price Target MT
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $500 From $456, Maintains Overweight Rating MT
Wells Fargo Adjusts Price Target on Vertex Pharmaceuticals to $555 From $540 MT
Vertex Pharmaceuticals Discloses 'Positive' Data From Phase 1/2 Trial of VX-880 to Treat Type 1 Diabetes MT
Vertex Pharmaceuticals, Inc. Announces Positive Results from Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes CI
Vertex Pharmaceuticals Has Pricing Accord for Cystic Fibrosis Drugs With UK National Health Service MT
Argus Adjusts Price Target on Vertex Pharmaceuticals to $550 From $465 MT
Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials MT
Vertex Pharmaceuticals Incorporated Presents Positive Long-Term Data on CASGEVY (Exagamglogene Autotemcel) CI
Vertex Pharmaceuticals Insider Sold Shares Worth $1,089,840, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,483,664, According to a Recent SEC Filing MT
Transcript : Vertex Pharmaceuticals Incorporated Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 11:20 AM
RBC Adjusts Price Target on Vertex Pharmaceuticals to $421 From $424 MT

Chart Vertex Pharmaceuticals Incorporated

Chart Vertex Pharmaceuticals Incorporated
More charts

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
Biotechnology & Medical Research
Calendar
02/08/2024 - Q2 2024 Earnings Release
Related indices
S&P 500
More about the company

Income Statement Evolution

More financial data

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
490.8 USD
Average target price
473.1 USD
Spread / Average Target
-3.62%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+20.63% 13TCr
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+23.21% 12TCr
ARGENX SE Stock argenx SE
+26.43% 2.77TCr
BIONTECH SE Stock BioNTech SE
-20.17% 2.03TCr
GENMAB A/S Stock Genmab A/S
-16.36% 1.68TCr
BEIGENE, LTD. Stock BeiGene, Ltd.
-18.07% 1.56TCr
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+11.92% 1.48TCr
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-47.70% 1.46TCr
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+58.32% 1.44TCr
INSMED INCORPORATED Stock Insmed Incorporated
+149.98% 1.25TCr
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. VRTX Stock
  4. News Vertex Pharmaceuticals Incorporated
  5. Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $589 From $577, Maintains Buy Rating